| 英文别名 |
Candesartan cilexetil;1-[[(cyclohexyloxy)carbonyl]oxy]ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole-7-carboxylate;1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate;Cadesartan cilexetil;Candesartan Cilexeti;TCV-116;2-Ethoxy-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester;TCV116;2-ethoxy-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-Benzimidazole-7-carboxylic acid 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester;TCY 116;Atacand;Blopress;Candestartan;Candesartanciletexil;Candesantan Cilexetil;CANDESARTAN CILEXITIL;Amias;Parapres;Kenzen;TCV 116;Candesartan (Cilexetil);CANDESARTAN CILEXTIL;candesartancilexetil;Candesartan cilexetil [USAN];C33H34N6O6;1H-Benzimidazolium, 7-carboxy-1-(2-((cyclohexylcarbonyl)oxy)ethyl)-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)-, hydroxide, inner salt, (+-)-;2-Ethoxy-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycar;(+-)-1-Hydroxyethyl 2-ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylate, cyclohexyl carbonate (ester);Spectrum_001707;CANDESARTAN CILEXETIL (MART.);Candesartan cilexetil, United States Pharmacopeia (USP) Reference Standard;C2635;Candesartan cilexetil- Bio-X;CANDESARTAN CILEXETIL (USP MONOGRAPH);H212/91;DTXCID50239;NSC758697;NS00006138;CANDESARTAN CILEXETIL [JAN];Camptothecine, Antibiotic for Culture Media Use Only;1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-ethoxy-1-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-1,3-benzodiazole-7-carboxylate;AB01274805_02;CANDESARTAN CILEXETIL [EP MONOGRAPH];HMS1922J09;Candesartan cilexetil (Atacand);L006257;KBio2_002187;(+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methylbenzimidazole-7-carboxylate;Spectrum2_000485;Candesartan 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester;Candesartan cilexetil for peak identification, European Pharmacopoeia (EP) Reference Standard;HMS3651I08;Atacand (TN);C07709;CANDESARTAN CILEXETIL [MART.];1-(Cyclohexyloxycarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazol-7-carboxylate;BCP9000480;1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate;2-Ethoxy-3-[2''-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester;BRD-A65671304-001-02-6;AC-204;Candesartan 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester;SCHEMBL40831;1261393-19-4;KBio2_004755;Ratacand;BCP22050;CHEMBL1014;Candesartan Cilexetil, Pharmaceutical Secondary Standard; Certified Reference Material;BSPBio_002691;D00626;KBioSS_002187;NCGC00095123-01;BDBM50318907;1H-Benzimidazole... |